{"result": "(\"entity\"<|>GALACTOSE<|>PERSON<|>Galactose is a simple sugar that is part of the lactose molecule and is significant in the context of galactosemia, as it cannot be properly metabolized by affected individuals.)\n##\n(\"entity\"<|>FAMILIARES<|>PERSON<|>Familiares refers to family members who may have a history of galactosemia, which is important for genetic counseling and prenatal diagnosis.)\n##\n(\"entity\"<|>TRATAMIENTO DIETÉTICO<|>EVENT<|>Dietary treatment is a crucial management strategy for individuals with galactosemia, focusing on the restriction of galactose intake to prevent complications.)\n##\n(\"entity\"<|>COMPLICACIONES A LARGO PLAZO<|>EVENT<|>Long-term complications refer to the potential health issues that can arise in individuals with galactosemia if dietary restrictions are not followed.)\n##\n(\"relationship\"<|>GALACTOSE<|>GALACTOSEMIA<|>Galactose is the sugar that individuals with galactosemia cannot metabolize, leading to the disorder<|>9)\n##\n(\"relationship\"<|>FAMILIARES<|>GALACTOSEMIA<|>Family history is significant in diagnosing and managing galactosemia, as it can indicate genetic predisposition<|>7)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>TRATAMIENTO DIETÉTICO<|>Dietary treatment is essential for managing galactosemia and preventing long-term complications<|>9)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>COMPLICACIONES A LARGO PLAZO<|>Failure to adhere to dietary restrictions in galactosemia can lead to long-term complications<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: -P eritrocitaria está eleva-                    De igual forma, en los pacientes en los que se sospe-\n   da pero habitualmente en niveles no tan altos                           che una galactosemia fuera del período neonatal, se\n   como en la forma clásica (> 10 mg/dl), y cuando                         determinarán los niveles bioquímicos de los metaboli-\n   se sigue la dieta libre de galactosa de forma co-                       tos y la actividad enzimática y posteriormente se reali-\n   rrecta se normaliza.                                                    zará estudio genético.\n•  Variante bioquímica de Galactosemia, con ac-                              Ante un neonato en el que se sospeche una galacto-\n   tividad GALT parcial residual >15% en eritrocitos.                      semia, con un primer screening positivo o con antece-\n   Los niveles de Gal-1-P en eritrocitos son mayores                       dentes familiares se debe comenzar tratamiento dieté-\n   de1 mg/dl sin tratamiento dietético, y normales si                      tico adecuado en espera de los resultados para evitar\n   se cumple la dieta sin galactosa. La más frecuente                      secuelas.\n---\n 226      BLOQUE: HIDRATOS DE CARBONO\n\n\n\n    En caso de que existan antecedentes familiares de                       durante la gestación no produce ningún beneficio\ngalactosemia, puede realizarse el diagnóstico prenatal                      en la prevención de las complicaciones a largo pla-\nmediante amniocentesis o biopsia corial para cuantifi-                      zo en el niño.\ncación de la actividad enzimática GALT o estudio de la                      Actualmente se están realizando estudios para ha-\nmutación conocida de la familia.                                            llar un mecanismo que consiga disminuir la sínte-\n                                                                            sis endógena de galactosa y así teóricamente po-\n2.2.2.     Objetivos nutricionales                                          der reducir las posibles complicaciones a largo\n                                                                            plazo, ya que, como se ha dicho, el tratamiento\n    Se debe iniciar tratamiento dietético inmediatamen-                     dietético no evita su aparición.\nte en todos los neonatos de los que se reciba un scree-                  •   Variante bioquímica. Hasta este momento no exis-\nning neonatal positivo en espera de confirmación, y en                       te suficiente evidencia científica para permitir a los\ngeneral en todos los individuos con actividad GALT                           pacientes con variante        Duarte    (D/ G) una ingesta\n≤ 10% y niveles de Gal-1-P > 10 mg/dl. En los recién                         normal, puesto que los datos publicados son con-\nnacidos de riesgo (esto es, con familiares con galacto-                      tradictorios. Sí parece que pueden tolerar ciertas\nsemia) se iniciará el tratamiento desde el nacimiento                        cantidades de galactosa, ya que aunque la activi-\nhasta recibir el resultado del screening neonatal.                           dad GALT se encuentra disminuida no está ausen-\n                                                                             te. Para evitar posibles secuelas se recomienda la\n    •  Galactosemia clásica y variante clínica de galacto-                   restricción de galactosa hasta el año de edad y\n       semia. El objetivo del tratamiento consiste en evi-                   entonces realizar un test de tolerancia mediante la\n       tar la ingesta de galactosa (y por lo tanto también                   determinación de los niveles de Gal-1-P en eritro-\n       de lactosa) lo más precozmente posible desde que                      citos tras dos semanas de incluir en la dieta los\n       exista la sospecha diagnóstica y durante toda la                      alimentos con galactosa, tanto lácteos como no\n       vida. Una dieta estricta contiene unos 40 mg de                       lácteos. Si los niveles son normales (< 1 mg/dl), el\n       galactosa al día. Se desconoce, sin embargo, qué                      paciente ya no precisaría ninguna restricción; en\n       cantidad exacta de galactosa puede ingerirse sin                      cambio, si los niveles están aumentados se deben\n       efectos tóxicos, por lo que se debe tomar la me-                      reinstaurar nuevamente las modificaciones dieté-\n       nor posible. Es objeto de debate lo restrictiva que                   ticas y reevaluar la tolerancia periódicamente cada\n       debe ser la dieta tras la lactancia, ya que al dejar                  4-6 meses.\n       de ser los productos lácteos la principal fuente ali-                Dada la ausencia de información a largo plazo\n       menticia, la producción endógena de galactosa es                     para los homocigotos D/ D, el manejo se realizará\n       mayor que la ingerida en la dieta; además, la apa-                   de forma similar a la variante Duarte (D/G).\n       rición de complicaciones tardías no se modifican\n       con el tratamiento dietético y el período de riesgo             2.2.3.    Recomendaciones dietéticas\n       de complicaciones agudas ya ha pasado. Por el\n       momento, hasta que exista mayor evidencia cien\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GALACTOSEMIA<|>EVENT<|>Galactosemia is a genetic metabolic disorder characterized by the inability to metabolize galactose, leading to various health complications if not managed properly.)\n##\n(\"entity\"<|>GALT<|>PERSON<|>GALT refers to the enzyme Galactose-1-phosphate uridylyltransferase, which is crucial for the metabolism of galactose and is often measured in patients suspected of having galactosemia.)\n##\n(\"entity\"<|>AMNIOCENTESIS<|>EVENT<|>Amniocentesis is a medical procedure used for prenatal diagnosis, including the quantification of GALT activity in suspected cases of galactosemia.)\n##\n(\"entity\"<|>BIOPSIA CORIAL<|>EVENT<|>Chorionic villus sampling (biopsia corial) is a prenatal test that can also be used to diagnose galactosemia by assessing enzyme activity or genetic mutations.)\n##\n(\"entity\"<|>NEONATAL SCREENING<|>EVENT<|>Neonatal screening is a public health program aimed at early detection of metabolic disorders, including galactosemia, in newborns.)\n##\n(\"entity\"<|>DIETA LIBRE DE GALACTOSA<|>EVENT<|>A galactose-free diet is a treatment approach for managing galactosemia, aimed at preventing the intake of galactose and its derivatives.)\n##\n(\"entity\"<|>GAL-1-P<|>PERSON<|>Gal-1-P refers to Galactose-1-phosphate, a substance whose levels are monitored in patients with galactosemia to assess the severity of the condition.)\n##\n(\"entity\"<|>VARIANTE DUARTE<|>EVENT<|>Duarte variant is a specific type of galactosemia that has a partial enzyme activity, which may allow for some dietary flexibility compared to classic galactosemia.)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>NEONATAL SCREENING<|>Neonatal screening is essential for the early detection of galactosemia, allowing for timely intervention and management<|>8)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>DIETA LIBRE DE GALACTOSA<|>A galactose-free diet is the primary treatment for managing galactosemia and preventing complications<|>9)\n##\n(\"relationship\"<|>GALT<|>GAL-1-P<|>GALT enzyme activity is measured by assessing the levels of Gal-1-P in erythrocytes to diagnose galactosemia<|>7)\n##\n(\"relationship\"<|>AMNIOCENTESIS<|>GALACTOSEMIA<|>Amniocentesis can be used for prenatal diagnosis of galactosemia by measuring enzyme activity<|>6)\n##\n(\"relationship\"<|>BIOPSIA CORIAL<|>GALACTOSEMIA<|>Chorionic villus sampling can also diagnose galactosemia by assessing enzyme activity or genetic mutations<|>6)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>VARIANTE DUARTE<|>Duarte variant is a specific form of galactosemia that presents differently than classic galactosemia<|>5)\n<|COMPLETE|>"}]}